Advanced technology
GE HealthCare’s most powerful whole-body gradient platform to date
State-of-the-art applications
Powered by a common suite of SIGNA imaging applications and deep-learning tools
Freedom and familiarity
Same look and feel as other GE HealthCare MRI scanners, for research or clinical use
Designed for advanced MR research as well as clinical translation, SIGNA 7T brings a plethora of innovations in a single system. Approximately five times more powerful than most clinical systems, SIGNA 7T is designed to detect subtle structures that may be significant for clinicians and researchers alike.
“The SIGNA 7.0T has allowed us to explore 23Na concentration changes associated with glioblastomas as well as response to ECT therapy for the treatment of depression”
Our SIGNA 7T combines innovative hardware with state-of-the-art software for overcoming common challenges with operating at ultra high fields.
Uncover new contrasts, such as Quantitative Susceptibility Mapping (QSM), for advancing neurological disorder research. Explore novel biomarkers for ischemic stroke characterization and uncover subtle structures with ultra-high resolution imaging with our SIGNA 7T platform.
Users have access to our latest state-of-the-art applications along with deep-learning tools like AIR x™ Brain and Knee as well as AIR™ Recon DL, while delivering the diagnostic confidence of an ultra-high-field system.
Our SIGNA 7T platform is equipped with GE HealthCare’s most powerful whole-body gradient system yet. With peak amplitude of 113 mT/m and a peak slew rate of 260 T/m/s, this scanner can properly leverage the clinical capabilities and research demands that users expect from a 7T.
Users can switch between clinical and research modes for easy protocol deployment. Our SIGNA 7T scanner share the same state-of-the-art software platform as GE HealthCare 1.5T and 3T product portfolio, enhancing ease of use and productivity
“In addition to an extensive 7T research program, the clinical protocols on our SIGNA 7T MRI scanner in Pisa include epilepsy, Parkinson’s and white matter diseases. We find susceptibility-weighted imaging, and the potential for quantitative susceptibility mapping, an indispensable tool for better delineation of microscopic brain features to provide insights on such conditions as neuronal tumor, focal cortical dysplasia and polymicrogyria.”
*SIGNA 7T is a configuration of SIGNA™ 7.0T. SIGNA 7.0T is FDA cleared and CE marked. Not available for sale in all regions.
